Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Mar;13(3):291-298.
doi: 10.1158/1940-6207.CAPR-19-0416. Epub 2020 Feb 12.

A Multi-Institutional Cohort of Therapy-Associated Polyposis in Childhood and Young Adulthood Cancer Survivors

Affiliations
Multicenter Study

A Multi-Institutional Cohort of Therapy-Associated Polyposis in Childhood and Young Adulthood Cancer Survivors

Leah H Biller et al. Cancer Prev Res (Phila). 2020 Mar.

Abstract

Prior small reports have postulated a link between gastrointestinal polyposis and childhood and young adulthood cancer (CYAC) treatment (therapy-associated polyposis; TAP), but this remains a poorly understood phenomenon. The aim of this study was to describe the phenotypic spectrum of TAP in a multi-institutional cohort. TAP cases were identified from eight high-risk cancer centers. Cases were defined as patients with ≥10 gastrointestinal polyps without known causative germline alteration or hereditary colorectal cancer predisposition syndrome who had a history of prior treatment with chemotherapy and/or radiotherapy for CYAC. A total of 34 TAP cases were included (original CYAC: 27 Hodgkin lymphoma, three neuroblastoma, one acute myeloid leukemia, one medulloblastoma, one nephroblastoma, and one non-Hodgkin lymphoma). Gastrointestinal polyposis was first detected at a median of 27 years (interquartile range, 20-33) after CYAC treatment. A total of 12 of 34 (35%) TAP cases had ≥50 colorectal polyps. A total of 32 of 34 (94%) had >1 histologic polyp type. A total of 25 of 34 (74%) had clinical features suggestive of ≥1 colorectal cancer predisposition syndrome [e.g., attenuated familial adenomatous polyposis (FAP), serrated polyposis syndrome, extracolonic manifestations of FAP, mismatch repair-deficient colorectal cancer, or hamartomatous polyposis] including 8 of 34 (24%) with features of multiple such syndromes. TAP is an apparently acquired phenomenon that should be considered in patients who develop significant polyposis without known causative germline alteration but who have had prior treatment for a CYAC. Patients with TAP have features that may mimic various hereditary colorectal cancer syndromes, suggesting multiple concurrent biologic mechanisms, and recognition of this diagnosis may have implications for cancer risk and screening.

PubMed Disclaimer

Conflict of interest statement

Disclosures/Conflict of Interest

LHB: no conflict of interest to report

CU: no conflict of interest to report

TGD: no conflict of interest to report

CAB: no conflict of interest to report

YC: no conflict of interest to report

AC: no conflict of interest to report

JMC: no conflict of interest to report

ESK: no conflict of interest to report

BHL: Advisory Board: Invitae, Speakers Bureau Myriad Genetics Lab

EL: no conflict of interest to report

RML: no conflict of interest to report

ML: no conflict of interest to report

ESM: no conflict of interest to report

RS: no conflict of interest to report

GI: no conflict of interest to report

FK: no conflict of interest to report

ES: no conflict of interest to report

JMW: no conflict of interest to report

MJH: no conflict of interest to report

MFK: no conflict of interest to report

ZKS: Immediate Family Member, Ophthalmology: Consulting/Advisory Role: Allergan, Adverum Biotechnologies, Alimera Sciences, Biomarin, Fortress Biotech, Genentech, Novartis, Optos, Regeneron, Regenxbio, Spark Therapeutics

SS: consultant for Myriad Genetics and Digital China Health Technologies and has rights to an inventor portion of the licensing revenue from PREMM5

MBY: no conflicts of interest to report

Figures

Figure 1:
Figure 1:
Colorectal polyps per TAP case, stratified by histologic type of polyp (if known).

Similar articles

Cited by

References

    1. Reulen RC, Frobisher C, Winter DL, Kelly J, Lancashire ER, Stiller CA, et al. Long-term risks of subsequent primary neoplasms among survivors of childhood cancer. JAMA. 2011;305(22):2311–2319. - PubMed
    1. Turcotte LM, Neglia JP, Reulen RC, Ronckers CM, Van Leeuwen FE, Morton LM, et al. Risk, risk factors, and surveillance of subsequent malignant neoplasms in survivors of childhood cancer: A review. J Clin Oncol. 2018;36(21):2145–2152. - PMC - PubMed
    1. Bhakta N, Liu Q, Ness KK, Baassiri M, Eissa H, Yeo F, et al. The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). Lancet. 2017;390(10112):2569–2582. - PMC - PubMed
    1. Teepen JC, Kok JL, van Leeuwen FE, Tissing WJE, Dolsma W V, van der Pal HJ, et al. Colorectal Adenomas and Cancers After Childhood Cancer Treatment: A DCOG-LATER Record Linkage Study. JNCI J Natl Cancer Inst. 2018;110(7):758–767. - PubMed
    1. Henderson TO, Oeffinger KC, Whitton J, Leisenring W, Neglia J, Meadows A, et al. Secondary Gastrointestinal Cancer in Childhood Cancer Survivors. Ann Intern Med. 2012;156(11):757–766. - PMC - PubMed

Publication types

MeSH terms

Substances